Research letterRecognition of atopic keratoconjunctivitis during treatment with dupilumab for atopic dermatitis
References (5)
- et al.
Atopic keratoconjunctivitis: a review
J Am Acad Dermatol
(2014) - et al.
Conjunctivitis in dupilumab clinical trials
Br J Dermatol
(2019)
There are more references available in the full text version of this article.
Cited by (4)
Dupilumab therapy in children aged 2–12 years with uncontrolled moderate-to-severe atopic dermatitis: A Chinese real-world study
2024, Journal of the European Academy of Dermatology and VenereologyVernal Keratoconjunctivitis: A Systematic Review
2023, Clinical Reviews in Allergy and ImmunologyDupilumab-Associated Adverse Events During Treatment of Allergic Diseases
2022, Clinical Reviews in Allergy and Immunology
Drs Ling and Greiner contributed equally to this article.
Funding sources: None.
Conflicts of interest: None disclosed.
IRB approval status: Determined by the University of Iowa IRB not to meet the regulatory definition of human subjects research (no. 201906723).
© 2020 by the American Academy of Dermatology, Inc.